Mylan's woes seen as a benefit for Indian drugmakers

30 November 2018

Netherlands-headquartered Mylan’s (Nasdaq: MYL) flagship oral solids facility getting a US Food and Drug Administration warning letter is being viewed as an advantage Indian drug majors. With several big Indian pharmaceutical companies expected to return to double-digit growth riding on a dynamic troika of recovery in sales in the USA, depreciation of the rupee against the dollar, and improving domestic demand, the Mylan episode has further added to this upswing, reports The Pharma Letter’s India correspondent.

Indian pharma companies with significant presence in the US generic market have been grappling with slow growth as a result of intense US generics pricing pressure. As drug companies aim to fill the temporary shortages caused due to regulatory challenges, agile Indian companies are stepping up to the plate.

The slowdown in production at Mylan's Morgantown site is set to provide a window of opportunity for Sun Pharma (BSE: 524715) to the tune of $79 million, Aurobindo Pharma to the tune of $40 million, and for Cadila Healthcare around $35 million, says analyst.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK